more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

Top 28% (71 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

National Vision (EYE) Q4 Earnings Top Estimates, Margins Up

by Zacks Equity Research Published on March 04,2021

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.

Masimo's (MASI) Rad-G with Temperature Receives CE Marking

by Zacks Equity Research Published on March 04,2021

Masimo's (MASI) Rad-G with Temperature, which aids clinicians in seamless assessment of key vital signs through a single device, gets CE marking.

medical

Abbott (ABT) Gets Canadian Nod for FreeStyle Libre Expanded Use

by Zacks Equity Research Published on March 04,2021

Abbott's (ABT) FreeStyle Libre is the only glucose sensing technology available in Canada to remotely monitor glucose status in an expectant mother to reduce exposure to COVID-19.

medical

Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF

by Zacks Equity Research Published on March 03,2021

Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.

medical

Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on March 03,2021

Veeva Systems' (VEEV) core Subscription business and Professional Service segments perform impressively in fiscal Q4.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research Published on March 03,2021

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y

by Zacks Equity Research Published on March 03,2021

Patterson Companies' (PDCO) fiscal third-quarter 2021 results benefit from strong segmental performance.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research Published on March 02,2021

Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.

medical

Zacks.com featured highlights include: Skyworks, ParkerHannifin, Toll Brothers, Abbott Lab and FedEx

by Zacks Equity Research Published on March 02,2021

Zacks.com featured highlights include: Skyworks, ParkerHannifin, Toll Brothers, Abbott Lab and FedEx

Is Abbott (ABT) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research Published on March 01,2021

Abbott (ABT) possesses solid growth attributes, which could help it handily outperform the market.

ABTPositive Net Change

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research Published on March 01,2021

DENTSPLY SIRONA (XRAY) witnesses consumable revenue growth in the fourth quarter.

medical

PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat

by Zacks Equity Research Published on March 01,2021

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.

medical

Here's Why You Should Add Abbott (ABT) to Your Portfolio

by Zacks Equity Research Published on March 01,2021

Investors continue to be optimistic about Abbott (ABT) due to a slew of product launches and regulatory approvals.

medical

Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research Published on March 01,2021

Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.

medical

5 Dividend Growth Stocks Poised for Outperformance

by Sweta Killa Published on March 01,2021

Dividend growth stocks like Skyworks Solutions (SWKS), ParkerHannifin (PH), Toll Brothers (TOL), Abbott Laboratories (ABT) and FedEx (FDX) seem poised to outperform.

February Ends in Green Amid Extreme Volatility: 5 Top Picks

by Nalak Das Published on March 01,2021

We have narrowed down our search to five corporate behemoths that suffered a blow in last month's turmoil. These are AAPL, MSFT, FB, ABT and DHR.